Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

Similar articles for PubMed (Select 23337027)

1.

From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012.

Caini S, Beck NS, Yacouba H, Maiga I, Chaibou I, Hinsa I, Adakal A, Issoufou A, Kim SH, Pezzoli L.

Vaccine. 2013 Mar 15;31(12):1597-603. doi: 10.1016/j.vaccine.2013.01.015. Epub 2013 Jan 19.

PMID:
23337027
2.

Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.

Kim SH, Pezzoli L, Yacouba H, Coulibaly T, Djingarey MH, Perea WA, Wierzba TF.

PLoS One. 2012;7(1):e29116. doi: 10.1371/journal.pone.0029116. Epub 2012 Jan 20.

3.

Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2012 Dec 21;61(50):1022-4.

4.
5.

Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination.

Collard JM, Issaka B, Zaneidou M, Hugonnet S, Nicolas P, Taha MK, Greenwood B, Jusot JF.

BMC Infect Dis. 2013 Dec 6;13:576. doi: 10.1186/1471-2334-13-576.

6.

Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.

Kristiansen PA, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, Clark TA, Misegades L, Martin SW, Thomas JD, Tiendrebeogo SR, Hassan-King M, Djingarey MH, Messonnier NE, Préziosi MP, Laforce FM, Caugant DA.

Clin Infect Dis. 2013 Feb;56(3):354-63. doi: 10.1093/cid/cis892. Epub 2012 Oct 19.

7.

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.

Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, Laforce FM, Avokey F, Djingarey MH, Messonnier NE, Tiendrébéogo SR, Clark TA.

Lancet Infect Dis. 2012 Oct;12(10):757-64. doi: 10.1016/S1473-3099(12)70168-8. Epub 2012 Jul 18.

PMID:
22818241
8.

Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.

Meyer SA, Kambou JL, Cohn A, Goodson JL, Flannery B, Medah I, Messonnier N, Novak R, Diomande F, Djingarey MH, Clark TA, Yameogo I, Fall A, Wannemuehler K.

Vaccine. 2015 Mar 17;33(12):1492-8. doi: 10.1016/j.vaccine.2015.01.043. Epub 2015 Jan 28.

PMID:
25636915
9.

Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.

Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Preziosi MP, Zuber PL, Perea W, Hugonnet S, Dellepiane de Rey Tolve N, Tevi-Benissan C, Clark TA, Mayer LW, Novak R, Messonier NE, Berlier M, Toboe D, Nshimirimana D, Mihigo R, Aguado T, Diomandé F, Kristiansen PA, Caugant DA, Laforce FM.

Vaccine. 2012 May 30;30 Suppl 2:B40-5. doi: 10.1016/j.vaccine.2011.12.073. Review.

PMID:
22607898
10.

Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].

Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbé M, Toralta J, Kodbesse B, Ngadoua C, Coldiron ME, Fermon F, Page AL, Djingarey MH, Hugonnet S, Harrison OB, Rebbetts LS, Tekletsion Y, Watkins ER, Hill D, Caugant DA, Chandramohan D, Hassan-King M, Manigart O, Nascimento M, Woukeu A, Trotter C, Stuart JM, Maiden MC, Greenwood BM.

Lancet. 2014 Jan 4;383(9911):40-7. doi: 10.1016/S0140-6736(13)61612-8. Epub 2013 Sep 12. Erratum in: Lancet. 2014 Jan 4;383(9911):30.

11.

Impact of vaccination during an epidemic of serogroup C meningococcal disease in Salvador, Brazil.

Cardoso CW, Pinto LL, Reis MG, Flannery B, Reis JN.

Vaccine. 2012 Aug 10;30(37):5541-6. doi: 10.1016/j.vaccine.2012.06.044. Epub 2012 Jun 27.

12.

Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.

Patel M, Lee CK.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001093. Review.

PMID:
15674874
13.

Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010.

Chaibou MS, Bako H, Salisou L, Yaméogo TM, Sambo M, Kim SH, Djingarey MH, Zuber PL, Perea WA, Pezzoli L.

Vaccine. 2012 Jul 27;30(35):5229-34. doi: 10.1016/j.vaccine.2012.06.006. Epub 2012 Jun 16.

PMID:
22709955
14.
15.

Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.

Noronha CP, Struchiner CJ, Halloran ME.

Int J Epidemiol. 1995 Oct;24(5):1050-7.

PMID:
8557439
16.

[An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].

Aplogan A, Batchassi E, Yakoua Y, Croisier A, Aleki A, Schlumberger M, Molina S, Sidatt M, Kaninda AV.

Sante. 1997 Nov-Dec;7(6):384-90. French.

PMID:
9503496
17.

Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

Croxtall JD, Dhillon S.

Drugs. 2012 Dec 24;72(18):2407-30. doi: 10.2165/11209580-000000000-00000. Review.

PMID:
23231026
18.

Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.

Arnold R, Galloway Y, McNicholas A, O'Hallahan J.

Vaccine. 2011 Sep 16;29(40):7100-6. doi: 10.1016/j.vaccine.2011.06.120. Epub 2011 Jul 29.

PMID:
21803101
19.
20.

Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.

de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, de Melker HE, Sanders EA, Berbers GA, van der Klis FR.

PLoS One. 2010 Aug 13;5(8):e12144. doi: 10.1371/journal.pone.0012144.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk